Get started
Author

Mary Gleeson

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
2016 · Sandy Amorim, Anastasios Stathis, et al. · The Lancet Haematology · 447
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
2017 · M. Gleeson, N. Counsell, et al. · Annals of Oncology · 93
PDF
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
2018 · Mary Gleeson, Clare Peckitt, et al. · The Lancet Haematology · 73
PDF
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London
2020 · B Russell, C Moss, et al. · Frontiers in Oncology · 64
PDF
Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London
2021 · Beth Russell, Charlotte L. Moss, et al. · British Journal of Cancer · 54
PDF
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐ CHOP ) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐ CHOP 14 versus 21 trial
2016 · Mary Gleeson, Eliza A. Hawkes, et al. · British Journal of Haematology · 52
Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
2023 · Emma Searle, Francesco Forconi, et al. · Blood · 38
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma
2021 · Olwen Westerland, Ashik Amlani, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 38
PDF
Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial
2020 · Mary Gleeson, Nicholas Counsell, et al. · British Journal of Haematology · 23
Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013
2016 · Mary Gleeson, Eliza A. Hawkes, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 22
Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post‐hematopoietic stem cell transplant for dyskeratosis congenita due to TINF 2 mutation
2013 · Niall O'Connell, Matthew Goodyer, et al. · Pediatric Transplantation · 18
Retinal vasculopathy in autosomal dominant dyskeratosis congenita due to TINF 2 mutation
2012 · Mary Gleeson, Aengus O'Marcaigh, et al. · British Journal of Haematology · 16
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
2023 · Rohan Shotton, Rachel Broadbent, et al. · Blood Advances · 14
PDF
Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL
2009 · Ronan Desmond, Karen Lynch, et al. · American Journal of Hematology · 13
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
2025 · Zulfa Omer, Alexey Danilov, et al. · Blood · 12
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital
2017 · Mary Gleeson, Clare Peckitt, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐ GEM ‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma
2014 · Sarah Barton, Eliza A. Hawkes, et al. · European Journal Of Haematology · 12
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
2023 · Allison Barraclough, James T. England, et al. · Haematologica · 11
PDF
The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial
2016 · Mary Gleeson, Andrew Jack, et al. · Blood · 11
Pb2331: an Ongoing First-in-human Phase 1 Trial of Nx-5948, an Oral Bruton’s Tyrosine Kinase (btk) Degrader, in Patients With Relapsed/refractory B Cell Malignancies
2023 · Kim Linton, Jeanette Doorduijn, et al. · HemaSphere · 9
R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial
2015 · Mary Gleeson, Eliza A Hawkes, et al. · Blood · 8
Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma
2015 · Mary Gleeson, Eliza A. Hawkes, et al. · Journal of Clinical Oncology · 8
PDF
A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies
2014 · Catherine Thieblemont, Anastasios Stathis, et al. · Blood · 8
Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
2024 · Euan Haynes, Kushani Ediriwickrema, et al. · Blood · 7
PDF
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study
2025 · Nirav Shah, Scott Huntington, et al. · Blood · 6
PDF
Works count: 70
Citation count: 1,124
H-index: 13
I10-index: 19
Year
Topic
Type